Abstract: This invention relates to oral care compositions, for example comprising a salt of a basic amino acid having a pH in solution of less than 7.5, an abrasive having a pH in solution of less than 7.5, and a fluoride ion source, and an acid selected from the group consisting of: a carboxylic acid (e.g., citric acid, lactic acid, glycolic acid, acetic acid, succinic acid, or fumaric acid), and an inorganic acid, wherein the inorganic acid is not phosphoric acid or sulfuric acid (e.g., wherein the inorganic acid is hydrochloric acid or sodium acid pyrophosphate), and to methods of using and of making these compositions.

Abstract: The invention also relates to processes for producing abuse deterrent pharmaceutical compositions comprising highly pure amphetamine and amphetamine-class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.

Abstract: The disclosure relates generally to polyglutamated antifolates, formulations containing liposomes filled with the polyglutamated antifolates, methods of making the polyglutamated antifolates and liposome containing formulations, and methods of using the polyglutamated antifolates and liposome containing formulations to treat hyerproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., an autoimmune disease such as rheumatoid arthritis).

Abstract: A method, and formulations for the method, for the treatment of hair loss is herein described. Typically, the method involves applying an exosome-based skincare product to skin affected by hair loss, such as the skin of the scalp. The exosome-based skincare product contains exosomes produced by and excreted from human umbilical mesenchymal stem cells cultured in vitro under specific conditions and then contained within a solvent. The hair loss may be caused by androgenic alopecia, alopecia areta, or telogen effulvium.

Abstract: A biological hair shape change composition including a macromolecular component, a small molecular component and an alkali agent component is provided. The macromolecular component includes a protease belonging to the class of alkaline proteases, and the small molecular component includes a peptide with reduction activity. Both the macromolecular component and the small molecular component are obtained from a fermentation product of Bacillus licheniformis and a keratin and/or keratin polymer-containing medium. Molecular weights of ingredients in the macromolecular component are greater than or equal to 3 kDa and are 3-1000 kDa, and molecular weights of ingredients in the small molecular component are less than 3 kDa and are 0.01-2.99 kDa.

Abstract: Compositions and methods for targeted delivery of active agents to cells are provided. The compositions comprise a wholly or partially double-stranded synthetic DNA carrier, and an active agent intercalated in double-stranded portions of the DNA carrier. The DNA carrier may also be linked to a targeting agent. The compositions are useful for delivering an active agent into a targeted cell type, for example a cytotoxic agent.

Abstract: Leave-on oral care compositions having good spreadability and improved retention property are provided for promoting Gum Health of a user. Leave-on oral care compositions can comprise a hyaluronic acid or a salt thereof, a polyacrylic acid as a mucoadhesive polymer, and an additional polymer.

Abstract: The disclosure relates generally to polyglutamated antifolates, formulations containing liposomes filled with alpha or D-gamma polyglutamated antifolates, methods of making the polyglutamated antifolates and liposome containing formulations, and methods of using polyglutamated antifolates and liposome containing formulations to treat hyerproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., an autoimmune disease such as rheumatoid arthritis).

Abstract: The disclosure relates generally to polyglutamated antifolates, formulations containing liposomes filled with alpha or D-gamma polyglutamated antifolates, methods of making the polyglutamated antifolates and liposome containing formulations, and methods of using polyglutamated antifolates and liposome containing formulations to treat hyerproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., an autoimmune disease such as rheumatoid arthritis).

Abstract: A drug-loaded nanofiber membrane includes a first fiber, a second fiber, and a drug. The drug is dispersed into the first fiber. The first fiber includes poly(lactic-co-glycolic acid) copolymer (PLGA copolymer), and the second fiber includes poly(p-dioxanone) (PDO).

Abstract: Described herein are systems and methods for attracting insects to a trap or surface containing insecticide. One embodiment described herein is an insect attractant releasing system comprising a quantity of a volatile insect attractant where the attractant is released at a defined rate and has a particular product lifetime under field conditions. In another embodiment, the attractant releasing system is integrated into an apparatus having insecticide immobilized on one or more surfaces where attracted insects can crawl or land and contact the insecticide, which subsequently kills the insects.

Abstract: A bactericidal and virucidal pharmaceutical composition for use on epithelial tissues such as pulmonary, nasal and oral tissues, which comprises a non-steroidal anti-inflammatory drug (NSAID) in a concentration between 5 and 500 mM and a salt, being the NSAID preferably solubilized in a hypertonic saline solution applicable in therapies for viral infections of the Herpes simplex type. The composition can be used in therapies for herpes simplex viral infections, be used as a bactericidal mouthwash, or be vehiculated to the lung by using a nebuliser, for cystic fibrosis.

Abstract: Biocide compositions efficacious for biofilm control, including treatment and/or prevention, comprising the synergistic combination of biocide(s) with a source of hydronium ions are disclosed. Methods of deactivating, removing and/or preventing biofilms with the compositions are also provided.

Abstract: Compositions are disclosed herein that comprise a mixture of at least one Albizia extract and a Magnolia extract. In some embodiments, the composition comprises a mixture of at least one Albizia extract enriched for one or more macrocyclic alkaloids and at least one Magnolia extract enrich for one or more lignans.

Abstract: An IL-15 super agonist (IL-15N72D:IL-15R?SU/IgG1Fc; N-803) increases circulating NK cells, effector memory and effector memory RA cells in post-allogeneic hematopoietic stem cell transplant patients (HCT). Methods of treatment include administration of N-803 to subjects in need of such treatment.

Abstract: The disclosure is directed to a biodegradable particle comprising a polyester or polyester blend, a first protein that binds to an immune cell, and a second protein that promotes proliferation and/or activation of immune cells, and a third soluble protein or small molecule encapsulated within the particle. The second protein is a fusion protein comprising at least a portion of an antibody and at least a portion of a cytokine (i.e., an immunocytokine). The disclosure also is directed to methods for treating a disease or condition in a subject (e.g., an autoimmune disease) comprising administering the aforementioned biodegradable particle to the subject.

Abstract: Disclosed is a composition for promoting hair growth and ameliorating, preventing or treating hair loss containing 2?-fucosyllactose (2?-FL) as an active ingredient, and a method for promoting hair growth or ameliorating, preventing or treating hair loss, the method comprising administering to a subject in need thereof 2?-fucosyllactose. Treatment with a combination of testosterone and 2?-fucosyllactose increases hair gloss, increases hair length, reduces a hair loss area, enhances hair cuticles, increases the number and size of hair follicles, and improves expression of proteins and genes related to hair proliferation and growth, compared to treatment with testosterone alone, thus being applicable as a substance for various food and pharmaceutical compositions based on effects of promoting hair growth, improving hair loss, and ameliorating, preventing or treating hair loss.

Abstract: The presently disclosed invention relates to products and methods of treating cancer in a patient comprising administering to the patient a pharmaceutically therapeutic dose of a chemotherapeutic, or any pharmaceutically acceptable salt, solvate, or prodrug thereof, conjugated to a nanocarrier. According to a further embodiment, the chemotherapeutic has a primary (1°) amine (—NH2) group in within a pharmaceutical structure of the chemotherapeutic structure. According to a further embodiment, the chemotherapeutic is one of a platinum-based pharmaceutical and an Anthracycline family pharmaceutical. According to a further embodiment, the chemotherapeutic is one of gemcitabine, methotrexate, cisplatin, oxaliplatin, doxorubicin, daunorubicine, idarubicine, and epirubicine. According to a further embodiment, the chemotherapeutic is either attached to the nanocarrier by means that includes covalent bonds or is attached by means that does not included covalent bonds.

Abstract: A preparation method and application of a biomimetic nano-protectant for detoxifying doxorubicin (DOX)-induced cardiac and systemic toxicity are provided. The preparation method comprises the following steps: obtaining and mixing DNA and protamine (Pro) to prepare DNA&Pro nanoparticles; reacting heterofunctional polyethylene glycol DSPE-PEG2000-MAL with PCM/KALA to prepare DSPE-PEG2000-PCM/KALA; inserting DSPE-PEG2000-PCM/KALA into a surface of Red Blood Cell Membrane (RBCM) to prepare PCM/KALA-RBCM; and mixing the RBCM-PCM/KALA with the DNA&Pro nanoparticles to prepare a biomimetic nano-protectant DNA&Pro@RBCM-PCM/KALA. The biomimetic nano-protectant prepared is applied to detoxification of DOX.

Abstract: The present application relates to a method for reduction and prevention of damaged skin stasis comprising applying a material containing water-soluble or water-insoluble copper compounds to said damaged skin.